Creative Medical Technology Holdings Inc (CELZ)

[gint1]

We are Golden CELZers!!!!!

To date the Company has reported therapeutic activity of ImmCelz® in models of rheumatoid arthritis4, stroke5, type 1 diabetes6, kidney failure7 and liver failure8," said Timothy Warbington, President and CEO of the Company. "Demonstration of enhancing graft survival in organ transplantation allows for a whole new area of medical progress. Our scientists suggest the superior efficacy of ImmCelz® for organ transplantation is that the cellular therapy suppresses rejection, while at the same time regenerates the organ after transplantation. It is known that the process of transplantation causes harm to the organ."